Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790324 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BLMNAMAPTNPSR1 | |
| SCHEMBL7790838 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BLMNAMAPTNPSR1 | |
| SCHEMBL7790715 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7788394 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BLMNAMAPTNPSR1 | |
| SCHEMBL7791932 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BMAPTMMP2 | |
| SCHEMBL7791935 | 0.82 | ITGB3 (0.47) | ITGB3ITGA2BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7012192 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7015828 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7015367 | 0.81 | ITGB3 (1.00) | ITGB3ITGA2BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7787513 | 0.81 | ITGB3 (0.49) | ITGB3ITGA2BMMP2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | TSAKLAKIDIS CHRISTOS (DE) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | CYP4B1, NR4A1, CYP3A43 | ITGB3 1193/4885ITGA2B 3222/4885LMNA 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.